These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24397608)

  • 1. Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.
    Beitland S; Platou ES; Sunde K
    Acta Anaesthesiol Scand; 2014 Mar; 58(3):266-72. PubMed ID: 24397608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.
    Michels G; Kochanek M; Pfister R
    Med Klin Intensivmed Notfmed; 2016 May; 111(4):302-9. PubMed ID: 26340799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
    Thomas SH; Behr ER
    Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.
    Napolitano C; Schwartz PJ; Brown AM; Ronchetti E; Bianchi L; Pinnavaia A; Acquaro G; Priori SG
    J Cardiovasc Electrophysiol; 2000 Jun; 11(6):691-6. PubMed ID: 10868744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obstructive Sleep Apnea in Patients with Congenital Long QT Syndrome: Implications for Increased Risk of Sudden Cardiac Death.
    Shamsuzzaman AS; Somers VK; Knilans TK; Ackerman MJ; Wang Y; Amin RS
    Sleep; 2015 Jul; 38(7):1113-9. PubMed ID: 26118557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
    Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
    Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.
    Etaee F; Tobin M; Vuppala S; Komaki A; Delisle BP; Di Biase L; Catanzaro JN; Natale A; Elayi CS
    J Interv Card Electrophysiol; 2022 Mar; 63(2):471-500. PubMed ID: 34674120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mexiletine in the management of long QT syndrome.
    Li G; Zhang L
    J Electrocardiol; 2018; 51(6):1061-1065. PubMed ID: 30497731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of drug induced QT interval prolongation.
    Ponte ML; Keller GA; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electromechanical window negativity in genotyped long-QT syndrome patients: relation to arrhythmia risk.
    ter Bekke RM; Haugaa KH; van den Wijngaard A; Bos JM; Ackerman MJ; Edvardsen T; Volders PG
    Eur Heart J; 2015 Jan; 36(3):179-86. PubMed ID: 25205533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.
    Lopez-Medina AI; Chahal CAA; Luzum JA
    Pharmacogenomics; 2022 Jun; 23(9):543-557. PubMed ID: 35698903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.